Radin

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Radin

Property Description
Active Ingredient Ranitidine Hydrochloride
Pharmacological Class Histamine H2-receptor antagonist (H2-blocker)
Common Form Oral tablets, solution, or syrup
General Purpose Gastric acid secretion inhibition
Origin Synthetic

What Type of Medicine is Radin, and What is its Composition?

Radin is classified as a synthetic, single-ingredient medication belonging to the therapeutic class of Histamine H2-receptor antagonists, commonly known as H2-blockers. The preparation's active compound is Ranitidine Hydrochloride. This compound is a product of chemical synthesis, establishing Radin as a non-naturally derived entity. As a single-ingredient product, it delivers only the therapeutic action of Ranitidine. The formulation is typically available as oral tablets and specialized oral solution or syrup preparations, with the latter forms often used for patient groups such as children.


Radin's Primary Action: What is its General Purpose?

The general purpose of Radin is to function as a highly effective antisecretory agent that significantly minimizes the production of acid within the stomach. Its primary therapeutic utility is fundamentally rooted in achieving powerful gastric acid secretion inhibition. The drug's mechanism involves blocking histamine signals to reduce acid output. By interfering with the signals that prompt the stomach to produce acid, Radin provides a crucial benefit in managing conditions characterized by gastric hypersecretion, thereby protecting the lining of the esophagus and stomach from excessive chemical irritation.

What side effects are possible with Radin?

Possible Side Effects and Safety Information

The safety profile for Radin (Ranitidine) is established by government regulatory authorities, with adverse effects classified by frequency and involvement of specific body systems.


Adverse Reaction Scope

The most common adverse effect documented in regulatory materials is headache. Other non-serious effects are generally uncommon and primarily involve the Gastrointestinal System, including symptoms such as abdominal pain/discomfort, nausea, and constipation.

Classification Example Adverse Reaction (from official labels)
Common Headache
Uncommon Abdominal discomfort, Nausea, Constipation
Rare/Very Rare Hypersensitivity, Blood count changes, Hepatitis

Serious adverse reactions are rare, but the official labeling documents effects on multiple systems, including severe blood dyscrasias (e.g., pancytopenia) and hepatitis (liver inflammation), sometimes with jaundice. Reversible mental confusion is also noted, particularly in older adults and the severely ill.


Safety-Related Restrictions and Considerations

The medicine is contraindicated for individuals with a history of acute porphyria. The regulatory documentation also emphasizes that the symptomatic relief provided by this medication does not exclude the presence of gastric malignancy. Furthermore, prolonged treatment has been associated with the potential for Vitamin B12 deficiency. Caution and possible dosage review are explicitly required for patients with renal impairment due to reduced clearance of the drug.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documentation for Ranitidine (Radin) defines the required actions and clinical manifestations that necessitate seeking emergency medical attention.

When to Seek Immediate Medical Help

Property Official Regulatory Documentation
Documented Overdose Presentations: Central Nervous System (CNS) effects such as confusion and motor coordination disturbances (gait abnormalities). Reports also indicate tachycardia (rapid heart rate) [Source: Regulatory Labeling].
Physiological Systems Affected (as stated in label): CNS and Cardiovascular System, with a potential for hypotension (low blood pressure) in cases of massive overdose [Source: Regulatory Labeling].
Population-specific Overdose Notes (if applicable): Patients who are elderly or have existing renal impairment (kidney issues) are noted to be at increased risk for CNS toxicity and confusion [Source: Regulatory Labeling].
Emergency-response statements (as written in official documents): Immediate medical attention is required following a confirmed or suspected overdose. The patient or caregiver must contact a Poison Control Center or emergency room immediately [Source: Regulatory Guidance].

Overdose Management and Constraint

The official management protocol is defined as symptomatic and supportive treatment because no specific antidote is known for Ranitidine overdose. Management procedures described in regulatory texts include intensive monitoring of the patient's vital signs and, if appropriate, procedures like gastric lavage or administration of activated charcoal to remove unabsorbed drug [Source: Regulatory Labeling]. The required intensive monitoring must include observation of cardiac function.

Therapeutic Uses of Radin

What Radin Treats: Main Uses and Benefits

Radin is relevant in situations where patients experience conditions characterized by episodic or fluctuating symptom patterns, where short-term, supportive relief is commonly needed. It provides support that helps ease the overall symptom burden and may contribute to improved day-to-day comfort during symptomatic periods. The therapeutic category is commonly applied across domains where additional symptomatic support is needed and is generally considered relevant in contexts involving heightened systemic burden.

Radin is commonly used to help manage symptoms related to heightened physiological activity and symptoms that interfere with daily functioning. It is relevant for easing symptom clusters that may become intense or disruptive, especially when symptoms appear suddenly or fluctuate.

“Applied in contexts where additional support for symptom management is needed, Radin helps patients cope more steadily with difficult episodes.”


Short-Term Support for Symptomatic Discomfort

This use of Radin is applied across domains where additional symptomatic support is needed. It is relevant in contexts marked by increased discomfort or tension, and may provide supportive relief when symptoms interfere with routine activities.

Management of Disruptive Symptom Groups

Radin is relevant for easing symptom clusters that may become intense or disruptive, particularly those that interfere with daily comfort and create noticeable physiological strain. It is used when groups of symptoms appear suddenly or fluctuate, and may assist with maintaining functional stability.

Quick Fact: Support for Symptoms related to physical discomfort

Regulatory References

  1. European Medicines Agency (EMA) guidance on its therapeutic category

Eligibility and Restrictions for Use

Official Eligibility and Contraindication Profile

Radin (Ranitidine) is an H2-blocker, and its eligibility for use is strictly defined by regulatory authorities based on patient population and pre-existing conditions.

Contraindicated Populations:

Category Official Regulatory Statement
Absolute Exclusion The medicine is contraindicated for patients with a known hypersensitivity to ranitidine or any of its formulation components [1]. It must be avoided in patients with a history of acute porphyria [1].
Condition-Specific Eligibility for self-treatment is restricted if symptoms suggest a gastric malignancy, as the medication may mask symptoms and delay diagnosis. This possibility must be excluded by a doctor [1].

Age- and Organ-Based Restrictions:

Category Official Regulatory Statement
Age Groups Use is established for adults and adolescents (ge 12 years). Prescription use is documented for pediatric patients (from 1 month to 16 years) under medical supervision [1]. Self-treatment (OTC) is not recommended for children under 12 years [1].
Renal Function Patients with impaired renal function (Creatinine clearance lt 50 mL/min) require conditional use, as the drug is primarily excreted by the kidneys. Use is permitted only with a required dosage adjustment and medical supervision [1].
Reproductive Status Use during pregnancy and lactation is generally not recommended unless specifically considered essential by a physician, based on data that Ranitidine crosses the placenta and is excreted into breast milk [1].

Official regulatory documents define who can and cannot use Radin by establishing absolute contraindications based on hypersensitivity and porphyria, setting age thresholds, and imposing conditional eligibility based on the status of renal function and reproductive status. This structure outlines mandatory exclusions and required cautions, strictly based on documented pharmacological profiles.

What should I know about interactions with other medicines?

Radin's official interaction profile is defined by its influence on pharmacokinetic (PK) processes, primarily through two distinct pathways: alteration of gastric pH and competition for renal transport systems. The increase in pH can lead to the reduced absorption and systemic exposure of co-administered medicines that require an acidic environment, such as the antifungal Ketoconazole or the antiviral Atazanavir. A second key domain involves the competition for the renal proximal tubular secretion site. This effect results in the increased plasma concentration of drugs like Procainamide and its active metabolite, N-acetylprocainamide. While Radin exhibits minimal inhibition of hepatic cytochrome P-450 enzymes at standard doses, the regulatory profile documents instances of increased exposure for certain enzyme substrates, including Triazolam and Midazolam, and altered prothrombin times for Warfarin. An important timing constraint exists for administration with high doses of oral Sucralfate (e.g., 2 g), which must be administered at least 2 hours after Radin to avoid interference. Furthermore, prolonged use of H2-receptor antagonists may prevent the normal absorption of Vitamin B12 from the diet. The profile also notes that Radin's total clearance is reduced and its half-life prolonged in patients with impaired renal function, a population-specific PK consideration.

Mechanism of Action

The mechanism involves Ranitidine (Radin) acting as a competitive antagonist on the Histamine H2 receptors ( H2R), which are situated on the gastric parietal cells. By occupying these receptors, the drug prevents the endogenous mediator, histamine, from binding and initiating its secretory signal.

Blocking the H2R effectively interrupts the intracellular cAMP signaling cascade, which translates the receptor signal into activity. This reduction in the necessary internal chemical cascade leads to the reduction in hydrogen ion ( H^+) output from the parietal cells. This alters the physiological process, resulting in an increase in the gastric pH (a measurable change in acidity).

The mechanism operates via receptor antagonism, engaging signaling that is specific to the histamine pathway. Its effect is primarily focused on this pathway, meaning the mechanism addresses only one of the three major secretagogue pathways for acid secretion. This limitation means the mechanism does not result in the total cessation of acid secretion.

Dosage and Administration Information

Instruction Map: How to use Radin — Official Administration Guidelines


Administration Scope

Feature Instruction Detail
Route of administration Primarily Oral; also approved for Intravenous (IV) and Intramuscular (IM) administration when oral intake is not feasible.
Dosing schedule Standard Treatment: 150 mg BID or 300 mg QD at bedtime. Maintenance: 150 mg QD at bedtime. Severe/Hypersecretory: Doses may be increased up to 6 grams per day in divided doses.
Timing in relation to meals (if applicable) May be taken with or without food. For prophylactic use, take 30 to 60 minutes before a meal.
Preparation requirements (if applicable) Effervescent tablet/granule forms must be fully dissolved in a glass of water before being consumed.
Age-group administration rules Pediatric: Dosing is weight-based (mg/kg) in divided daily doses. Renal Impairment: Dose reduction to 150 mg every 24 hours is required for patients with creatinine clearance < 50 mL/min.
Special procedural conditions The parenteral route (IV/IM) is used only when the oral route is clinically not feasible. IV bolus administration requires a slow injection rate.

Instruction Classifications (High-Level)

Classification Official Use Principle
Administration method type Systemic (Oral & Parenteral).
Frequency pattern Daily (QD, BID) or Intermittent (e.g., Q6-8H).
Protocol Basis Standardized Dosing Protocols.
Use-context constraints Treatment is classified as 4 to 8 week short-term courses or long-term maintenance use.

Resulting Procedural Structure

Official step sequence:

  • Select the appropriate route, primarily oral or parenteral if non-oral intake is necessary.
  • Administer the 150 mg or 300 mg dose based on the required daily frequency (once or twice daily) or apply the 150 mg per 24 hours renal adjustment if applicable.
  • Ensure that effervescent forms are dissolved, or IV forms are properly diluted and infused slowly.

Connection to the overall use protocol: The official usage protocol dictates the exact amount and timing of Radin, ensuring that dosage is adjusted based on physiological clearance capacity (renal function) and that the method of intake (oral vs. injection) is tied to feasibility. This protocol standardizes the use over time by defining clear transitions between the time-limited acute treatment phase and the potentially long-term maintenance pattern.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Radin


Evidence for Studied Indications

Radin was studied for short-term relief related to acid discomfort in adults, primarily through randomized controlled trials (RCTs) and meta-analyses. These studies research examined symptom changes, focusing on patient-reported outcomes describing perceived discomfort over short follow-up durations.

Research was also studied for whether the medication was associated with changes in the healing of duodenal and gastric ulcers, and erosions of the esophagus (erosive esophagitis). The evidence base for healing includes RCTs and systematic reviews that examined objective markers, such as endoscopic healing rate. Findings indicate patterns of physical healing that research highlights over the acute treatment phase.

For pathological acid hypersecretion (rare conditions), research was studied for primarily through observational case series and specialized physiological studies. These studies research examined whether the medication was associated with changes in gastric acid output over time, with findings often reported in the context of case reports or small groups.


Evidence in Special Populations and Long-term Follow-up

Radin was evaluated in research exploring its use in pediatric populations, including infants, for acid-related symptoms. For older adults, evidence is often derived from the general adult trials. Data for certain groups remain insufficient, and sample sizes were modest in many of these specialized pediatric cohorts.

Studies exploring the durability of the medication's effect are generally separate from the acute trials. Overall, long-term effects are not fully established, and there is limited information for long-term outcomes that measure quality of life over periods exceeding one year.


Evidence Gaps and Areas of Uncertainty

Research limitations include follow-up durations were limited in many acute symptomatic trials. Furthermore, some of the most consistent findings data show patterns related to only physiological surrogate markers, such as pH and fluid volume (as seen in preoperative studies). This evidence highlights what is known — and what is still uncertain regarding the true clinical impact of those physiological changes.

Key Studies & References

  1. Ranitidine and prevention of pulmonary aspiration syndrome
  2. Successful Lifetime/Long-Term Medical Treatment of Acid Hypersecretion in Zollinger-Ellison Syndrome (ZES)

Frequently Asked Questions (FAQ)

Common questions about Radin (FAQ)


Q: How long does it typically take for Radin to start working?

Clinical data reported in regulatory documents indicate that the reduction of stomach acid may begin to occur as quickly as one hour after taking a single oral dose. The inhibitory effect on gastric acid secretion has been described as lasting for up to 12 hours. Peak concentrations of the drug in the blood are generally reached within 1 to 3 hours after administration.


Q: Is it normal to feel [General feeling] after starting Radin?

Official labeling documents the most common adverse reaction reported is a headache. Other uncommon, non-serious effects include abdominal discomfort, nausea, and constipation. Official guidance indicates that any new or persistent symptoms should be discussed with a healthcare provider.


Q: Is Radin considered safe for use in older adults?

Use in older adults is possible, but caution is noted in official documents due to potential age-related changes in kidney function, which can slow the body's clearance of the drug. The regulatory labeling also notes that reversible mental confusion has been observed, particularly in older and severely ill patients, which informs clinical evaluation.


Q: Can women who are planning to become pregnant use Radin?

Studies in animal models did not show evidence of impaired fertility or harm to the fetus. However, because there are no adequate, well-controlled studies involving women who are pregnant or planning to become pregnant, use is generally mentioned as appropriate only when the potential benefit is clearly needed and judged to outweigh any potential risk by a healthcare professional.


Q: Can Radin make a person feel dizzy or tired?

Official regulatory documents do not list general dizziness or fatigue (tiredness) as common side effects. However, the official labeling notes that in rare cases, reversible mental confusion has been observed. This is a central nervous system effect noted in the product information.


Q: What is the maximum duration of treatment with Radin mentioned in studies?

The recommended duration of use depends on the specific condition being addressed. For short-term symptomatic relief, regulatory sources typically advise a maximum continuous self-treatment period of two weeks. Prescription use for conditions like ulcers involves short-term courses, potentially followed by a maintenance regimen, the duration of which is assessed by a healthcare provider.


Q: What should I do if I think I'm having an allergic reaction to Radin?

Official health sources advise that if you suspect signs of a severe hypersensitivity reaction, such as difficulty breathing, hives, or swelling of the face, lips, or throat, emergency medical attention should be sought immediately. A known hypersensitivity to the drug is listed as an absolute reason not to use Radin.


Q: Is Radin known to interact with birth control pills?

Official labeling documents the drug's potential to alter the systemic levels of many co-administered medications, largely due to changing stomach acidity. However, official regulatory sources do not explicitly list an interaction between Radin and oral contraceptive pills.


Q: Does Radin require any routine blood tests during treatment?

Official labeling is associated with rare but potentially serious effects on blood counts and the liver. However, the documentation does not mandate routine blood test monitoring for all patients taking Radin. A healthcare provider may order laboratory tests to monitor specific organ function, especially for long-term use.


Q: What kind of specialist typically prescribes Radin?

Radin may be prescribed by a variety of healthcare professionals, including General Practitioners. Due to its therapeutic indications for conditions like peptic ulcers and reflux esophagitis, which involve the digestive system, it is also commonly managed by specialists like Gastroenterologists.


Q: How does Radin compare generally to [Name of similar drug]?

Radin is classified as a Histamine H2-receptor antagonist (H2-blocker) and works by blocking specific signals to reduce stomach acid production. Other similar drugs, such as Proton Pump Inhibitors (PPIs), are in a different drug class and use a separate mechanism to achieve acid reduction. The choice between these classes is a medical consideration based on the specific condition.


Q: Is Radin available in a generic version?

Yes. Radin's active ingredient is Ranitidine, and it is generally available in its generic form, Ranitidine Hydrochloride, as well as under various brand names. Generic formulations are approved based on the same regulatory standards for quality and effectiveness as brand-name products.


Q: Is Radin a blood thinner?

No. Radin is classified as a Histamine H2-receptor antagonist (H2-blocker), whose primary function is to reduce the production of stomach acid. It is not classified as an anticoagulant, or 'blood thinner,' though official labeling does note that it can alter the systemic levels of certain anticoagulants like Warfarin.


Q: What is the definition of a 'serious' side effect of Radin?

Official regulatory documents define serious side effects as rare events that may include effects requiring medical intervention or hospitalization. Examples documented in the safety profile include severe blood count changes (blood dyscrasias) and hepatitis (liver inflammation), sometimes with jaundice.


Q: How long does Radin stay in the body?

The time it takes for half of the drug to be eliminated from the body (the elimination half-life) is approximately 2 to 3 hours in most adults with normal kidney function. Elimination is slower in patients with reduced kidney function, which is noted as a factor in dose adjustment considerations.


Q: Can I take Radin if I am allergic to similar-sounding drugs?

Official documentation specifies that Radin is contraindicated for known hypersensitivity to Ranitidine itself. Since Radin belongs to the H2-blocker class of medications, a healthcare provider must carefully consider a patient's known sensitivities to other drugs in that class before prescribing it.


Q: What are the reported results of the main clinical trials for Radin?

Clinical trial results reported by regulators confirm the expected effects of the drug. Studies showed that the drug was associated with a significant reduction in gastric acid secretion and found patterns of physical healing for conditions like ulcers and esophagitis over the acute treatment phase.


Q: Is the effectiveness of Radin affected by body weight?

For adults, standard dosing is not typically based on body weight. However, official labeling notes that for pediatric patients, dosing is determined using a weight-based calculation. The dosage is also required to be adjusted for all patients with impaired kidney function.


Q: What is the legal status of Radin internationally?

The drug's approval and legal status vary globally and is governed by each country's regulatory body. It has been approved by major regulatory bodies, including the FDA (U.S.) and the EMA (Europe), although its regulatory status has been subject to changes and reapprovals in many markets.


Q: Is there a Black Box Warning on the labeling for Radin?

Official drug labeling for Radin does not currently carry a Black Box Warning, which is the most stringent safety warning required by the FDA. However, in the past, all Ranitidine products were subject to a broad market recall by regulators due to concerns regarding a specific impurity that could increase over time in some stored products.


Q: Can Radin be used to treat other conditions besides the main one?

Official regulatory documents list several approved indications for the medication beyond the most common uses. These include treatment for conditions such as Zollinger-Ellison Syndrome (a rare condition causing extreme acid production) and prophylaxis for GI hemorrhage from stress ulceration in seriously ill patients.

How should Radin be stored and disposed of?

The storage and disposal of Radin (Ranitidine) must follow strict conditions specified in the official regulatory labeling.

Storage Requirements

Storage Condition Requirement Specified in Labeling
Temperature Range Store tablets at controlled room temperature (20 C to 25 C).
Container & Protection Keep in the original container with the desiccant; keep the bottle tightly closed and away from excess heat and moisture.
Child Safety Keep out of the sight and reach of children to prevent accidental exposure.
In-Use Stability Unused tablets must be discarded after 3 months (90 days) of first opening the bottle, or by the expiration date, whichever is sooner.

Disposal Requirements

Expired or unused Radin should be disposed of by taking it to an authorized drug take-back program. If this option is not available, the product may be disposed of in the household trash by mixing it with an undesirable substance (like coffee grounds or cat litter) and sealing it in a container. Do not flush the medicine down the toilet or pour it down the drain unless specifically instructed to do so by the labeling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Radin found in:

A-Z Index: